Kailera widens Q1 net loss to $78.9 million as R&D spending rises
Kailera Therapeutics reported a first-quarter 2026 net loss of $78.9 million, up from $18.0 million a year earlier, as research and development expenses rose to $70.9 million from $10.1 million. The company said its cash, cash equivalents and marketable securities of $581.9 million, plus $718.8 million in gross IPO proceeds, will fund operations into mid-2028, and the filing reports no revenue for the period.
Key points
- Net loss was $78.9 million for the quarter ended March 31, 2026, compared with $18.0 million a year earlier.
- R&D expenses were $70.9 million versus $10.1 million, a $60.7 million increase tied to product candidate development and related costs.
- General and administrative expenses were $13.8 million versus $10.3 million.
- Cash, cash equivalents and marketable securities totaled $581.9 million at March 31, 2026, and are expected to fund operations into mid-2028.
The filing
Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.